PDS Biotechnology Corp — Director's Dealing 2015

Nov 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2015-11-16

Reporting Person: MIDDLEKAUFF W BRADFORD (Senior VP, GC and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-11-16	Stock Option (Right to Purchase)	$14.92	A	80000	Acquired	2015-11-16	Common Stock (80000)	Direct

Footnotes

F1: This option, representing a right to purchase a total of 80,000 shares of Common Stock, will become exercisable on October 30, 2016, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.